Volume 208, Issue 1 p. 91-99

Original Paper

ILK over-expression in human colon cancer progression correlates with activation of β-catenin, down-regulation of E-cadherin and activation of the Akt–FKHR pathway

V Bravou,

V Bravou

Department of Anatomy, School of Medicine, University of Patras, 26500 Rio Patras, Greece

Search for more papers by this author

G Klironomos,

G Klironomos

Department of Anatomy, School of Medicine, University of Patras, 26500 Rio Patras, Greece

Search for more papers by this author

E Papadaki,

E Papadaki

Department of Anatomy, School of Medicine, University of Patras, 26500 Rio Patras, Greece

Search for more papers by this author

S Taraviras,

S Taraviras

Department of Pharmacology, School of Medicine, University of Patras, 26500 Rio Patras, Greece

Search for more papers by this author

J Varakis,

Corresponding Author

J Varakis

[email protected]

Department of Anatomy, School of Medicine, University of Patras, 26500 Rio Patras, Greece

Department of Anatomy, School of Medicine, University of Patras, 26500 Rio Patras, Greece.Search for more papers by this author

V Bravou,

V Bravou

Department of Anatomy, School of Medicine, University of Patras, 26500 Rio Patras, Greece

Search for more papers by this author

G Klironomos,

G Klironomos

Department of Anatomy, School of Medicine, University of Patras, 26500 Rio Patras, Greece

Search for more papers by this author

E Papadaki,

E Papadaki

Department of Anatomy, School of Medicine, University of Patras, 26500 Rio Patras, Greece

Search for more papers by this author

S Taraviras,

S Taraviras

Department of Pharmacology, School of Medicine, University of Patras, 26500 Rio Patras, Greece

Search for more papers by this author

J Varakis,

Corresponding Author

J Varakis

[email protected]

Department of Anatomy, School of Medicine, University of Patras, 26500 Rio Patras, Greece

Department of Anatomy, School of Medicine, University of Patras, 26500 Rio Patras, Greece.Search for more papers by this author

First published: 08 November 2005

https://doi.org/10.1002/path.1860

Citations: 74

Share a link

Email
Facebook
Twitter
LinkedIn
Reddit
Wechat

Abstract

Integrin-linked kinase (ILK) has been implicated in the development and progression of several human malignancies. However, the role of ILK in human colon cancer progression is not well established, neither have its possible in vivo downstream effectors in the disease been identified. We studied, by immunohistochemistry, ILK, β-catenin, E-cadherin, p-Akt and p-FKHR protein expression in 125 primary colon carcinomas and 45 corresponding lymph node metastases. ILK was expressed in 98.4% of the primary tumours and in 100% of metastatic lesions. The levels of ILK expression correlated strongly with tumour invasion, tumour grade and stage and were significantly higher in metastatic tumours. Activation of β-catenin, down-regulation of E-cadherin and activation of the Akt–FKHR pathway correlated significantly with both ILK expression and tumour progression parameters. In conclusion, our results suggest that ILK may have an important role in progression of human colon cancer, possibly through in vivo regulation of β-catenin, E-cadherin and Akt pathways. Our study also provides some evidence implicating p-FKHR in human colon carcinogenesis and ILK signalling. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

References

1Bienz M, Clevers H. Linking colorectal cancer to Wnt signalling. Cell 2000; 103: 311–320.
2Alexander N, Wong CS, Pignatelly M. B-catenin—a linchpin in colorectal carcinogenesis. Am J Pathol 2002; 160: 389–402.
3Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al. Variable β-catenin expression in colorectal cancers indicates tumour progression driven by the tumour environment. Proc Natl Acad Sci USA 2001; 98: 10 356–10 361.
4Ougolkov AV, Yamashita K, Mai M, Minamoto T. Oncogenic β-catenin and MMP-7(matrilysin) co-segregate in late-stage clinical colon cancer. Gastroenterology 2002; 122(1): 60–71.
5Dorudi S, Sheffield JP, Poulsom R, Northover JM, Hart IR. E-cadherin expression in colorectal cancer. An immunohistochemical and in situ hybridization study. Am J Pathol 1993; 142: 981–986.
6Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, et al. Regulation of cell adhesion and anchorage-dependent growth by a new β1-integrin-linked kinase. Nature 1996; 379: 91–96.
7Wu C, Dedhar S. Integrin-linked kinase (ILK) and its interactors: a new paradigm for coupling of extracellular matrix to actin cytoskeleton and signalling complexes. J Cell Biol 2001; 155(4): 505–510.
8Dedhar S, Williams B, Hannigan G. Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Trends Cell Biol 1999; 9: 319–323.
9Persad S, Dedhar S. The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metast Rev 2003; 22: 375–384.
10Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005; 5: 51–63.
11Oloumi A, Mc Phee T, Dedhar S. Regulation of E-cadherin expression and β-catenin/Tcf transcriptional activity by integrin-linked kinase. Biochim Biophys Acta 2004; 1691: 1–15.
12Graff JR, Deddens JA, Konicek BW, Colligan BM, Hurst BM, Carter HW, Carter JH. Integrin-linked kinase expression increases with prostate tumour grade. Clin Cancer Res 2001; 7: 1987–1991.
13Dai DL, Makretsov N, Campos EI, Huang C, Zhou Y, Huntsman D, et al. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 2003; 9: 4409–4414.
14Ahmed N, Riley C, Oliva K, Stutt E, Rice G, Quinn M. Integrin-linked kinase increases with ovarian tumour grade and it is sustained by peritoneal tumour fluid. J Pathol 2003; 201: 229–237.
15Novak A, Hsu SC, Leung-Hagesteijn C, Radeva G, Papkoff R, Montesano R, et al. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and β-catenin signalling pathways. Proc Natl Acad Sci USA 1998; 95: 4374–4379.
16Wu C, Keightley SY, Leung-Hagesteijn C, Radeva G, Coppolino S, Goicoechea S, et al. Integrin-linked kinase regulates fibronectin-matrix assembly, E-cadherin expression and tumourigenicity. J Biol Chem 1998; 273: 528–536.
17Tan C, Costello P, Sanghera J, Dominguez D, Baulida J, de Hereros AG, Dedhar S. Inhibition of integrin-linked kinase suppresses β-catenin-Lef/Tcf-dependent transcription and expression of E-cadherin repressor snail, in APC^−/− human colon carcinoma cells. Oncogene 2001; 20: 133–140.
18Bravou V, Klironomos G, Papadaki E, Stefanou D, Varakis J. Integrin-linked kinase (ILK) expression in human colon cancer. Br J Cancer 2003; 89: 2340–2341.
19Marotta A, Parhar K, Owen D, Dedhar S, Salh B. Characterisation of integrin linked-kinase signalling in sporadic human colon cancer. Br J Cancer 2003; 88: 1755–1762.
20Rena G, Guo S, Cichy SC, Unterman TG, Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 1999; 274: 17 179–17 183.
21Tang ED, Nunez G, Barr FG, Guan KL. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 1999; 274: 16 741–16 746.
22Siegel S., Castellan NJ Jr. Nonparametric Statistics for the Behavioral Sciences, 2nd edn. McGraw-Hill: New York, 1988; 190–243.
23Delcommenne M, Tan C, Gray V, Ruell L, Woodgett J, Dedhar S. Phosphoiniside-3-OH kinase-dependent regulation of GSK-3 and PKB/AKT by the integrin-linked kinase (ILK). Proc Natl Acad Sci USA 1998; 95: 11 211–11 216.
24Troussard AA, Mawji NM, Ong C, Mui A, St-Arnaud R, Dedhar S. Conditional knock-out of the integrin-linked kinase demonstrated an essential role in protein kinase B/Akt activation. J Biol Chem 2003; 278(25): 22 374–22 378.
25Burgering BM, Kops GJ. Cell cycle and death control: long live Forkheads. Trends Biochem Sci 2002; 27: 352–360.
26Nickolson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381–395.
27Persad S, Atwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, Dedhar S. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 2000; 97: 3207–3212.
28Yau C, Wheeler JJ, Sutton KL, Hedley DW. Inhibition of integrin-linked kinase by a small molecule inhibitor QLT0254, inhibits the PI3K/PKB/mTOR, Stat3 and FKHR pathways and tumour growth and enhances gemcitabine-induced apoptosis in human orthotopic pancreatic cancer xenografts. Cancer Res 2005; 65(4): 1497–1504.
29Tan C, Cruet-Hennequart S, Troussard A, et al. Regulation of tumour angiogenesis by integrin-linked kinase (ILK). Cancer Cell 2004; 5: 79–90.
30Marotta A, Tan C, Gray V, et al. Deregulation of integrin-linked kinase (ILK) signalling in colonic polyposis. Oncogene 2001; 20: 6250–6257.
31Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumourigenesis. Nature 1992; 359: 235–237.
32Crawford HC, Fingleton BM, Rudolph-Owen LA, Heppner Goss KJ, Rubinfeld B, Polakis P, Matrisian LM. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumours. Oncogene 1999; 18: 2883–2891.
33Grandl D, Kuhl M, Wedlich D. The Wnt/wg signal transducer β-catenin controls fibronectin expression. Mol Cell Biol 1999; 19: 5576–5587.
34Thiery JP. Epithelial–mesenchymal transition in tumour progression. Nat Rev Cancer 2002; 2: 442–454.
35Kang Y, Massague J. Epithelial–mesenchymal-transitions: twist in development and metastasis. Cell 2004; 118: 277–279.
36Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumour progression. Ann N Y Acad Sci 2004; 1014: 155–163.
37Somarisi A, Howarth A, Goswami D, Dedhar S, Roskelley CD. Over-expression of integrin-linked kinase mesenchymally transforms mammary epithelial cells. J Cell Sci 2001; 114(6): 1125–1136.
38Itoh N, Yamakawa M, et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumour progression in human colorectal carcinoma. Cancer 2002; 94(12): 3127–3133.
39Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Santo A, Wang H, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004; 25(11): 2053–2059.
40Cheong JW, Eom JI, Maeng HY, Lee ST, Hahn JS, Ko YW, Min YH. Constitutive phosphorylation of FKHR transcription factor as a prognostic variable in acute myeloid leukemia. Leuk Res 2003; 27(12): 1159–1162.
41Khaleghpour K, Li Y, Banville D, Yu Z, Shen S. Involvement of PI3-kinase pathway in progression of colon adenocarcinoma. Carcinogenesis 2004; 25(2): 241–248.

Citing Literature

Volume208, Issue1

January 2006

Pages 91-99

ILK over-expression in human colon cancer progression correlates with activation of β-catenin, down-regulation of E-cadherin and activation of the Akt–FKHR pathway

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

ILK over-expression in human colon cancer progression correlates with activation of β-catenin, down-regulation of E-cadherin and activation of the Akt–FKHR pathway

Abstract

References

Citing Literature

References

Related

Information